Advertisement
Canada markets close in 6 hours 26 minutes

  • S&P/TSX

    21,585.85
    -2.03 (-0.01%)
     

  • S&P 500

    5,481.67
    +8.44 (+0.15%)
     

  • DOW

    38,827.30
    +49.20 (+0.13%)
     

  • CAD/USD

    0.7280
    -0.0009 (-0.13%)
     

  • CRUDE OIL

    80.60
    +0.27 (+0.34%)
     

  • Bitcoin CAD

    88,940.29
    -1,019.54 (-1.13%)
     

  • CMC Crypto 200

    1,351.59
    -37.81 (-2.72%)
     

  • GOLD FUTURES

    2,332.30
    +3.30 (+0.14%)
     

  • RUSSELL 2000

    2,022.01
    +15.85 (+0.79%)
     

  • 10-Yr Bond

    4.2460
    -0.0330 (-0.77%)
     

  • NASDAQ

    17,864.90
    +7.88 (+0.04%)
     

  • VOLATILITY

    12.62
    -0.13 (-1.02%)
     

  • FTSE

    8,186.88
    +44.73 (+0.55%)
     

  • NIKKEI 225

    38,482.11
    +379.67 (+1.00%)
     

  • CAD/EUR

    0.6781
    -0.0006 (-0.09%)
     
MARKETS LIVE BLOG:

S&P 500, NASDAQ HOVER NEAR RECORD HIGHS AT OPEN

U.S. retail sales rose at slower-than-expected pace in May amid high interest rates, inflation

Kura Oncology to Participate in Jefferies Global Healthcare Conference

Kura Oncology, Inc.
·2 min read
Kura Oncology, Inc.
Kura Oncology, Inc.

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Jefferies Global Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 3:00 p.m. ET / 12:00 p.m. PT on June 5, 2024. A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay following the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in NPM1-mutant R/R AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in NPM1-mutant and KMT2A-rearranged newly diagnosed and R/R AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent HNSCC (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn.

ADVERTISEMENT

Contacts

Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com

Media:
Alexandra Weingarten
Associate Director, Corporate Communications &
Investor Relations
(858) 500-8822
alexandra@kuraoncology.com